<p>Madrigal Pharmaceuticals（纳斯达克股票代码：MDGL - 获取免费报告）在周五发布的报告中，HC Wainwright 将其目标股价从 568.00 美元上调至 620.00 美元，Benzinga 报道。该公司目前对这家生物制药公司的股票给予 “买入” 评级。HC Wainwright 的目标股价意味着该股票相较于之前收盘价有 11.96% 的潜在上涨空间。</p>
<ul>
<li>MarketBeat 周报 – 09/08 - 09/12</li>
</ul>
<p>其他研究分析师最近也对该公司发布了研究报告。瑞银集团在 8 月 12 日的研究报告中重申了对 Madrigal Pharmaceuticals 的 “买入” 评级，并将目标股价上调至 523.00 美元（之前为 458.00 美元）。花旗集团在 11 月 5 日的报告中重申了对 Madrigal Pharmaceuticals 的 “跑赢大盘” 评级。派珀·桑德勒在 10 月 15 日的研究报告中将 Madrigal Pharmaceuticals 的目标股价从 400.00 美元上调至 540.00 美元，并给予该公司 “增持” 评级。B. Riley 在 9 月 29 日的报告中将 Madrigal Pharmaceuticals 的目标股价从 460.00 美元上调至 560.00 美元，并给予该股票 “买入” 评级。最后，Citizens Jmp 在 11 月 5 日的研究报告中将 Madrigal Pharmaceuticals 的目标股价从 485.00 美元上调至 527.00 美元，并给予该公司 “市场跑赢大盘” 评级。十三位股票研究分析师对该股票给予了 “买入” 评级，一位给予了 “持有” 评级，一位给予了 “卖出” 评级。根据 MarketBeat 的数据，Madrigal Pharmaceuticals 的共识评级为 “适度买入”，共识目标股价为 553.50 美元。</p>
<p><strong>查看我们最新的 MDGL 研究报告</strong></p>
<h2>Madrigal Pharmaceuticals 股价上涨 2.1%</h2>
<ul>
<li>CoreWeave 和 Madrigal 的内部交易闪现看涨信号</li>
</ul>
<p>Madrigal Pharmaceuticals 的股票在周五交易中上涨了 11.65 美元，达到 553.77 美元。该股票的交易量为 108,002 股，而其平均交易量为 370,878 股。Madrigal Pharmaceuticals 的 1 年最低价为 265.00 美元，1 年最高价为 577.90 美元。该股票的 50 日简单移动平均价为 454.65 美元，200 日简单移动平均价为 370.97 美元。该公司的速动比率为 4.78，流动比率为 5.11，债务与股本比率为 0.17。该公司的市值为 125.8 亿美元，市盈率为-43.23，贝塔值为-1.04。</p>
<p>Madrigal Pharmaceuticals（纳斯达克股票代码：MDGL - 获取免费报告）最后一次公布季度财报是在 11 月 4 日。该生物制药公司报告每股收益（EPS）为-5.08 美元，低于市场共识预期的-2.01 美元，差距为-3.07 美元。Madrigal Pharmaceuticals 的股本回报率为-38.38%，净利润率为-54.68%。研究分析师平均预计 Madrigal Pharmaceuticals 在当前财政年度的每股收益为-23.47 美元。</p>
<h2>内部买入和卖出</h2>
<ul>
<li>诺和诺德：GLP-1 销售的新推动力即将到来</li>
</ul>
<p>在其他新闻中，董事 Kenneth Bate 在 11 月 5 日的交易中出售了 16,575 股该股票。该股票的平均售价为 484.30 美元，总价值为 8,027,272.50 美元。出售完成后，该董事直接持有 2,627 股公司股票，价值约为 1,272,256.10 美元。这代表着他们持股比例减少了 86.32%。该交易已在与证券交易委员会的法律文件中披露，可以通过此超链接访问。此外，董事 Richard S. Levy 在 11 月 13 日的交易中出售了 8,500 股该公司的股票。该股票的平均售价为 520.96 美元，总交易额为 4,428,160.00 美元。出售完成后，该董事在公司持有 21,197 股，价值约为 11,042,789.12 美元。该交易使其持股比例减少了 28.62%。有关此次出售的更多细节可在官方 SEC 披露中找到。在过去 90 天内，内部人士共出售了 32,354 股公司股票，价值为 15,699,173 美元。内部人士持有公司股票的比例为 21.50%。</p>
<h2>机构资金流入和流出</h2>
<p>几家机构投资者和对冲基金最近对该股票的持仓进行了调整。Envestnet Asset Management Inc.在第一季度将其在 Madrigal Pharmaceuticals 的持股增加了 1.8%。Envestnet Asset Management Inc.目前持有 15,270 股该生物制药公司的股票，价值为 5,058,000 美元，此前在该期间内又购买了 269 股。安联资产管理公司在第一季度将其在 Madrigal Pharmaceuticals 的持仓增加了 59.1%。安联资产管理公司目前持有 1,556 股该生物制药公司的股票，价值为 515,000 美元，此前在上个季度又收购了 578 股。Universal Beteiligungs und Servicegesellschaft mbH 在第一季度购买了 Madrigal Pharmaceuticals 的新股份，价值约为 652,000 美元。Assetmark Inc.在第一季度将其在 Madrigal Pharmaceuticals 的持股增加了 24.0%。Assetmark Inc.目前持有 5,183 股该生物制药公司的股票，价值为 1,717,000 美元，此前在该期间内又收购了 1,003 股。最后，LPL Financial LLC 在第一季度将其在 Madrigal Pharmaceuticals 的持仓增加了 490.5%。LPL Financial LLC 目前持有 30,822 股该生物制药公司的股票，价值为 10,209,000 美元，此前在上个季度又购买了 25,602 股。机构投资者持有公司 98.50% 的股票。</p>
<h2>关于 Madrigal Pharmaceuticals</h2>
<p>（获取免费报告）</p>
<p>Madrigal Pharmaceuticals, Inc.是一家临床阶段的生物制药公司，专注于开发用于治疗美国非酒精性脂肪性肝炎（NASH）的治疗药物。其主要产品候选药物是 resmetirom，一种针对肝脏的甲状腺激素受体β激动剂，目前正在进行 NASH 的三期临床试验。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票，而非 Madrigal Pharmaceuticals</li>
<li>金融服务股票投资</li>
<li>4 只高风险成长股，价格低于 15 美元，值得关注</li>
<li>英国市场假期有哪些？如何投资和交易</li>
<li>沃尔玛股票在稳健的第三季度后大幅上涨——未来增长更强劲</li>
<li>寻找并盈利交易 52 周低点的股票</li>
<li>微软的 AI 超级工厂可能推动股票反弹</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TURHTA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TURHTA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Madrigal Pharmaceuticals 吗？</h2>
<p>在考虑 Madrigal Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前... 而 Madrigal Pharmaceuticals 并不在名单上。</p>
<p>虽然 Madrigal Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Madrigal制药

<p>HC Wainwright 将 Madrigal Pharmaceuticals 的目标股价从 568 美元上调至 620 美元，维持 “买入” 评级，显示出 11.96% 的潜在上涨空间。其他分析师也给予了积极评级，普遍目标价为 553.50 美元。Madrigal 的股票上涨 2.1%，报 553.77 美元。该公司报告的季度每股收益为（5.08 美元），未能达到预期。内部交易出现显著的股票出售，机构投资者调整了他们的持仓。Madrigal 的市值为 125.8 亿美元，市盈率为 -43.23</p>

<p>Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) had its price target lifted by HC Wainwright from $568.00 to $620.00 in a report issued on Friday,Benzinga reports. The firm currently has a &#34;buy&#34; rating on the biopharmaceutical company's stock. HC Wainwright's price target points to a potential upside of 11.96% from the stock's previous close.</p>
<div class="lb-trans"><p>Madrigal Pharmaceuticals（纳斯达克股票代码：MDGL - 获取免费报告）在周五发布的报告中，HC Wainwright 将其目标股价从 568.00 美元上调至 620.00 美元，Benzinga 报道。该公司目前对这家生物制药公司的股票给予 “买入” 评级。HC Wainwright 的目标股价意味着该股票相较于之前收盘价有 11.96% 的潜在上涨空间。</p>
</div><ul>
<li>MarketBeat Week in Review – 09/08 - 09/12</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周报 – 09/08 - 09/12</li>
</ul>
</div><p>Other research analysts also recently issued research reports about the company. UBS Group restated a &#34;buy&#34; rating and issued a $523.00 target price (up previously from $458.00) on shares of Madrigal Pharmaceuticals in a research note on Tuesday, August 12th. Citigroup reiterated an &#34;outperform&#34; rating on shares of Madrigal Pharmaceuticals in a report on Wednesday, November 5th. Piper Sandler boosted their price target on Madrigal Pharmaceuticals from $400.00 to $540.00 and gave the company an &#34;overweight&#34; rating in a research note on Wednesday, October 15th. B. Riley increased their price objective on Madrigal Pharmaceuticals from $460.00 to $560.00 and gave the stock a &#34;buy&#34; rating in a report on Monday, September 29th. Finally, Citizens Jmp raised their price objective on shares of Madrigal Pharmaceuticals from $485.00 to $527.00 and gave the company a &#34;market outperform&#34; rating in a research report on Wednesday, November 5th. Thirteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Madrigal Pharmaceuticals has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $553.50.</p>
<div class="lb-trans"><p>其他研究分析师最近也对该公司发布了研究报告。瑞银集团在 8 月 12 日的研究报告中重申了对 Madrigal Pharmaceuticals 的 “买入” 评级，并将目标股价上调至 523.00 美元（之前为 458.00 美元）。花旗集团在 11 月 5 日的报告中重申了对 Madrigal Pharmaceuticals 的 “跑赢大盘” 评级。派珀·桑德勒在 10 月 15 日的研究报告中将 Madrigal Pharmaceuticals 的目标股价从 400.00 美元上调至 540.00 美元，并给予该公司 “增持” 评级。B. Riley 在 9 月 29 日的报告中将 Madrigal Pharmaceuticals 的目标股价从 460.00 美元上调至 560.00 美元，并给予该股票 “买入” 评级。最后，Citizens Jmp 在 11 月 5 日的研究报告中将 Madrigal Pharmaceuticals 的目标股价从 485.00 美元上调至 527.00 美元，并给予该公司 “市场跑赢大盘” 评级。十三位股票研究分析师对该股票给予了 “买入” 评级，一位给予了 “持有” 评级，一位给予了 “卖出” 评级。根据 MarketBeat 的数据，Madrigal Pharmaceuticals 的共识评级为 “适度买入”，共识目标股价为 553.50 美元。</p>
</div><p><strong>View Our Latest Research Report on MDGL</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 MDGL 研究报告</strong></p>
</div><h2>Madrigal Pharmaceuticals Trading Up 2.1%</h2>
<div class="lb-trans"><h2>Madrigal Pharmaceuticals 股价上涨 2.1%</h2>
</div><ul>
<li>CoreWeave and Madrigal's Insider Trades Flash Bullish Signals</li>
</ul>
<div class="lb-trans"><ul>
<li>CoreWeave 和 Madrigal 的内部交易闪现看涨信号</li>
</ul>
</div><p>Shares of Madrigal Pharmaceuticals stock traded up $11.65 during trading on Friday, hitting $553.77. The stock had a trading volume of 108,002 shares, compared to its average volume of 370,878. Madrigal Pharmaceuticals has a 1 year low of $265.00 and a 1 year high of $577.90. The stock has a 50 day simple moving average of $454.65 and a 200 day simple moving average of $370.97. The company has a quick ratio of 4.78, a current ratio of 5.11 and a debt-to-equity ratio of 0.17. The company has a market capitalization of $12.58 billion, a PE ratio of -43.23 and a beta of -1.04.</p>
<div class="lb-trans"><p>Madrigal Pharmaceuticals 的股票在周五交易中上涨了 11.65 美元，达到 553.77 美元。该股票的交易量为 108,002 股，而其平均交易量为 370,878 股。Madrigal Pharmaceuticals 的 1 年最低价为 265.00 美元，1 年最高价为 577.90 美元。该股票的 50 日简单移动平均价为 454.65 美元，200 日简单移动平均价为 370.97 美元。该公司的速动比率为 4.78，流动比率为 5.11，债务与股本比率为 0.17。该公司的市值为 125.8 亿美元，市盈率为-43.23，贝塔值为-1.04。</p>
</div><p>Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last announced its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported ($5.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.01) by ($3.07). Madrigal Pharmaceuticals had a negative return on equity of 38.38% and a negative net margin of 54.68%. On average, research analysts expect that Madrigal Pharmaceuticals will post -23.47 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Madrigal Pharmaceuticals（纳斯达克股票代码：MDGL - 获取免费报告）最后一次公布季度财报是在 11 月 4 日。该生物制药公司报告每股收益（EPS）为-5.08 美元，低于市场共识预期的-2.01 美元，差距为-3.07 美元。Madrigal Pharmaceuticals 的股本回报率为-38.38%，净利润率为-54.68%。研究分析师平均预计 Madrigal Pharmaceuticals 在当前财政年度的每股收益为-23.47 美元。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买入和卖出</h2>
</div><ul>
<li>Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon</li>
</ul>
<div class="lb-trans"><ul>
<li>诺和诺德：GLP-1 销售的新推动力即将到来</li>
</ul>
</div><p>In other news, Director Kenneth Bate sold 16,575 shares of the stock in a transaction that occurred on Wednesday, November 5th. The stock was sold at an average price of $484.30, for a total value of $8,027,272.50. Following the completion of the sale, the director directly owned 2,627 shares of the company's stock, valued at approximately $1,272,256.10. This represents a 86.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. Also, Director Richard S. Levy sold 8,500 shares of the firm's stock in a transaction on Thursday, November 13th. The stock was sold at an average price of $520.96, for a total transaction of $4,428,160.00. Following the completion of the sale, the director owned 21,197 shares in the company, valued at approximately $11,042,789.12. The trade was a 28.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 32,354 shares of company stock valued at $15,699,173. Insiders own 21.50% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，董事 Kenneth Bate 在 11 月 5 日的交易中出售了 16,575 股该股票。该股票的平均售价为 484.30 美元，总价值为 8,027,272.50 美元。出售完成后，该董事直接持有 2,627 股公司股票，价值约为 1,272,256.10 美元。这代表着他们持股比例减少了 86.32%。该交易已在与证券交易委员会的法律文件中披露，可以通过此超链接访问。此外，董事 Richard S. Levy 在 11 月 13 日的交易中出售了 8,500 股该公司的股票。该股票的平均售价为 520.96 美元，总交易额为 4,428,160.00 美元。出售完成后，该董事在公司持有 21,197 股，价值约为 11,042,789.12 美元。该交易使其持股比例减少了 28.62%。有关此次出售的更多细节可在官方 SEC 披露中找到。在过去 90 天内，内部人士共出售了 32,354 股公司股票，价值为 15,699,173 美元。内部人士持有公司股票的比例为 21.50%。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Several institutional investors and hedge funds have recently made changes to their positions in the stock. Envestnet Asset Management Inc. increased its holdings in Madrigal Pharmaceuticals by 1.8% in the 1st quarter. Envestnet Asset Management Inc. now owns 15,270 shares of the biopharmaceutical company's stock valued at $5,058,000 after buying an additional 269 shares during the period. Allianz Asset Management GmbH boosted its position in shares of Madrigal Pharmaceuticals by 59.1% during the 1st quarter. Allianz Asset Management GmbH now owns 1,556 shares of the biopharmaceutical company's stock valued at $515,000 after acquiring an additional 578 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in Madrigal Pharmaceuticals in the first quarter valued at about $652,000. Assetmark Inc. increased its stake in Madrigal Pharmaceuticals by 24.0% in the first quarter. Assetmark Inc. now owns 5,183 shares of the biopharmaceutical company's stock valued at $1,717,000 after acquiring an additional 1,003 shares during the period. Finally, LPL Financial LLC raised its position in Madrigal Pharmaceuticals by 490.5% in the first quarter. LPL Financial LLC now owns 30,822 shares of the biopharmaceutical company's stock worth $10,209,000 after purchasing an additional 25,602 shares in the last quarter. Institutional investors own 98.50% of the company's stock.</p>
<div class="lb-trans"><p>几家机构投资者和对冲基金最近对该股票的持仓进行了调整。Envestnet Asset Management Inc.在第一季度将其在 Madrigal Pharmaceuticals 的持股增加了 1.8%。Envestnet Asset Management Inc.目前持有 15,270 股该生物制药公司的股票，价值为 5,058,000 美元，此前在该期间内又购买了 269 股。安联资产管理公司在第一季度将其在 Madrigal Pharmaceuticals 的持仓增加了 59.1%。安联资产管理公司目前持有 1,556 股该生物制药公司的股票，价值为 515,000 美元，此前在上个季度又收购了 578 股。Universal Beteiligungs und Servicegesellschaft mbH 在第一季度购买了 Madrigal Pharmaceuticals 的新股份，价值约为 652,000 美元。Assetmark Inc.在第一季度将其在 Madrigal Pharmaceuticals 的持股增加了 24.0%。Assetmark Inc.目前持有 5,183 股该生物制药公司的股票，价值为 1,717,000 美元，此前在该期间内又收购了 1,003 股。最后，LPL Financial LLC 在第一季度将其在 Madrigal Pharmaceuticals 的持仓增加了 490.5%。LPL Financial LLC 目前持有 30,822 股该生物制药公司的股票，价值为 10,209,000 美元，此前在上个季度又购买了 25,602 股。机构投资者持有公司 98.50% 的股票。</p>
</div><h2>About Madrigal Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 Madrigal Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.</p>
<div class="lb-trans"><p>Madrigal Pharmaceuticals, Inc.是一家临床阶段的生物制药公司，专注于开发用于治疗美国非酒精性脂肪性肝炎（NASH）的治疗药物。其主要产品候选药物是 resmetirom，一种针对肝脏的甲状腺激素受体β激动剂，目前正在进行 NASH 的三期临床试验。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Madrigal Pharmaceuticals</li>
<li>Financial Services Stocks Investing</li>
<li>4 High-Risk Growth Stocks Under $15 to Watch This Fall</li>
<li>What Are the U.K. Market Holidays? How to Invest and Trade</li>
<li>Walmart Stock Surges After a Solid Q3—Stronger Growth Ahead</li>
<li>Find and Profitably Trade Stocks at 52-Week Lows</li>
<li>Microsoft’s AI Superfactory Could Power a Stock Rally</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而非 Madrigal Pharmaceuticals</li>
<li>金融服务股票投资</li>
<li>4 只高风险成长股，价格低于 15 美元，值得关注</li>
<li>英国市场假期有哪些？如何投资和交易</li>
<li>沃尔玛股票在稳健的第三季度后大幅上涨——未来增长更强劲</li>
<li>寻找并盈利交易 52 周低点的股票</li>
<li>微软的 AI 超级工厂可能推动股票反弹</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TURHTA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=MDGL"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Madrigal Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Madrigal Pharmaceuticals 吗？</h2>
</div><p>Before you consider Madrigal Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Madrigal Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Madrigal Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前... 而 Madrigal Pharmaceuticals 并不在名单上。</p>
</div><p>While Madrigal Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Madrigal Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Madrigal 制药（NASDAQ:MDGL）在 HC Wainwright 被设定了新的目标价为 620.00 美元